FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 224 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease August 18, 2021 What People in Asian American and Pacific Islander Communities Should Know... September 5, 2023 Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... September 9, 2025 As Use of Genomic Data Expands in Cancer Care, Patients Share... December 3, 2019 Load more HOT NEWS Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... How MRI add-ons could accelerate the development of new treatments Is there a right way to check your body for cancer?
